EUCTR2005-001627-11-IT
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia
YAMANOUCHI PHARMA0 sites882 target enrollmentNovember 2, 2005
DrugsOMNIC
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- YAMANOUCHI PHARMA
- Enrollment
- 882
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adultsennox-Gastaut syndrome (LGS)MedDRA version: 17.1Level: PTClassification code 10048816Term: Lennox-Gastaut syndromeSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2014-002940-42-ESGW Research Ltd120
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC) - N/AThis study will evaluate the antitumor activity of RAD001 versus placebo in patientswith subependymal giant cell astrocytomas (SEGA) associated with TuberousSclerosis Complex (TSC).EUCTR2007-006997-27-DEovartis Pharma Services AG99
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia - RESTORETS (lower urinary tract symptoms) associated with BPH (benign prostatic hyperplasia)EUCTR2005-001627-11-PTYamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)1,051
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia - RESTOREEUCTR2005-001627-11-FIYamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)1,051
Active, not recruiting
Phase 1
Evaluation of Efficacy and Safety of Sarilumab in Patients with GCAGiant Cell ArteritisMedDRA version: 20.0Level: LLTClassification code 10018250Term: Giant cell arteritisSystem Organ Class: 100000004866Therapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2017-002988-18-BESanofi-Aventis Recherche & Développement508